Trials / Conditions / Stage IV Primary Peritoneal Cancer AJCC v8

Stage IV Primary Peritoneal Cancer AJCC v8

18 registered clinical trials studyying Stage IV Primary Peritoneal Cancer AJCC v8 — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in S NCT06855706	Roswell Park Cancer Institute	N/A
Withdrawn	Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients W NCT03735589	Roswell Park Cancer Institute	Phase 1 / Phase 2
Withdrawn	ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer NCT05368506	OHSU Knight Cancer Institute	EARLY_Phase 1
Recruiting	PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer NCT05465941	Mayo Clinic	Phase 2
Active Not Recruiting	Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage NCT05276973	National Cancer Institute (NCI)	Phase 1
Recruiting	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Tr NCT05415709	Ohio State University Comprehensive Cancer Center	EARLY_Phase 1
Recruiting	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448	University of Washington	Phase 1
Completed	Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients NCT05047926	Mayo Clinic	N/A
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534	National Cancer Institute (NCI)	Phase 1
Withdrawn	Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520	Pamela Munster	Phase 1
Recruiting	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary NCT04575935	M.D. Anderson Cancer Center	Phase 3
Recruiting	Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers NCT03968406	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian NCT04095364	NRG Oncology	Phase 3
Active Not Recruiting	Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cance NCT03943173	M.D. Anderson Cancer Center	EARLY_Phase 1
Active Not Recruiting	Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistan NCT03907527	Precigen, Inc	Phase 1
Completed	Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986	Roswell Park Cancer Institute	Phase 1 / Phase 2